Home › Research › Drug development
Association between exenatide use and incidence of Alzheimer's disease
Bo Zhou, Julie Zissimopoulos, Hasan Nadeem, Matthew A Crane, Dana Goldman, John A Romley. Alzheimer's & dementia (New York, N. Y.), 2021-02-14
Topic: Drug trials: efficacy and safety
Plain-language summary
The sample was mostly female (65%), White (76%), and 74 years old on average. Exenatide users were more likely to be male (38% vs. 35%), White (87% vs. 76%), and younger (by 4.2 years) than non-users. Each additional 30-day-equivalent claim was associated with a 2.4% relative reduction in incidence (odds ratio 0.976; 95% confidence interval 0.963-0.989; P < .001). There was no evidence of unmeasured confounding. Exenatide use is associated with a reduced incidence of AD among Medicare beneficiaries aged 65 years or older with T2DM. The association shown in this study warrants consideration by clinicians prescribing insulin sensitizing agents to patients.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Zhou, B., Zissimopoulos, J., Nadeem, H., Crane, M. A., Goldman, D., & Romley, J. A. (2021). Association between exenatide use and incidence of Alzheimer's disease. Alzheimer's & dementia (New York, N. Y.). https://doi.org/10.1002/trc2.12139
Vancouver
Zhou B, Zissimopoulos J, Nadeem H, Crane MA, Goldman D, Romley JA. Association between exenatide use and incidence of Alzheimer's disease. Alzheimer's & dementia (New York, N. Y.). 2021. doi:10.1002/trc2.12139. PMID: 33614900.
BibTeX
@article{zhou2021-33614900,
author = {Zhou, Bo and Zissimopoulos, Julie and Nadeem, Hasan and Crane, Matthew A and Goldman, Dana and Romley, John A},
title = {{Association between exenatide use and incidence of Alzheimer's disease}},
journal = {Alzheimer's \& dementia (New York, N. Y.)},
year = {2021},
doi = {10.1002/trc2.12139},
pmid = {33614900},
url = {https://doi.org/10.1002/trc2.12139}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The sample was mostly female (65%), White (76%), and 74 years old on average.
- Exenatide users were more likely to be male (38% vs. 35%), White (87% vs. 76%), and younger (by 4.2 years) than non-users.
- Each additional 30-day-equivalent claim was associated with a 2.4% relative reduction in incidence (odds ratio 0.976; 95% confidence interval 0.963-0.989; P < .001).
- There was no evidence of unmeasured confounding.
- Exenatide use is associated with a reduced incidence of AD among Medicare beneficiaries aged 65 years or older with T2DM.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designretrospective cohort
- Participants342,608
- Effect size2.4%
- Evidence strengthModerate
How this study scored 77/100
Published in a leading specialty journal, and it is a retrospective cohort study, reconstructed from past records. Scored zero for randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 43 of the 56 points we could judge it on, which is 77 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia (New York, N. Y.)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 7 / 12 | A retrospective cohort study, reconstructed from past records |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2021 — within 6 year(s) of the newest study here |
| Sample size | 4 / 4 | 342,608 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 33614900) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 43 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 43 of the 56 points we could judge it on is 77 out of 100. |
| Total | 77 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development from nearby years
Also tagged “cholinesterase”
272 studies in the library carry the topic tag “cholinesterase”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 272 tagged studies.